Skip links
medicine capsule on an Indian Rupee note
Copy or Compete? How India’s patent law harms its own drug industry’s ability to innovate

Copy or Compete? How India’s patent law harms its own drug industry’s ability to innovate

in Tags

Section 3(d) of India’s patent law may be putting India at a competitive disadvantage. The data presented in this research note shows it is preventing Indian generic pharmaceutical companies from developing new formulations, compositions, and combinations of existing medicines, which they instead undertake and commercialise abroad.

The European Commission’s pharmaceutical innovation incentives review is at risk of serious overreach

The European Commission’s pharmaceutical innovation incentives review is at risk of serious overreach

The European Commission (EC) outlined its plans to introduce a manufacturing waiver for Supplementary Protection Certificates (SPCs). If adopted, it would open the door for generic manufacturers to export medicines outside the EU while the SPC is still in force.